Predominance of CXCR4 tropism in HIV-1 CRF14_BG strains from newly diagnosed infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 246-253

  Pérez álvarez, Lucía ^a   Delgado, Elena ^a   Vega, Yolanda ^a   Montero, Vanessa ^a   Cuevas, Teresa ^a   Fernández García, Aurora ^a   García Riart, Beatriz ^a   Pé rez Castro, Sonia ^b   Rodríguez Real, Ricardo ^c   López á lvarez, María José ^d   Fernández Rodríguez, Ricardo ^e   Lezaun, María Jesús ^f   Ordóñez, Patricia ^g   Ramos, Carmen ^h   BereciartuaElena, ⁱ   Calleja, Sara ^j   Sánchez García, Ana M ^a   Thomson, Michael M ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^c HOSPITAL MONTECELO   (Spain)

^d Hospital Lucus Augusti   (Spain)

^e Servicio Gallego de Salud   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

^g Universidad de La Coruña   (Spain)

^h HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j Department of Cardiac Surgery   (Spain)

more..

Author keywords

Antiretroviral therapy; Coreceptors; HIV

Indexed keywords

ARGININE; CHEMOKINE RECEPTOR CXCR4; LYSINE; METHIONINE; THREONINE; TRYPTOPHAN; VIRUS RNA;

AMINO ACID SEQUENCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYLOGENY; SEXUAL TRANSMISSION; VIRAL TROPISM; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY; CORECEPTORS; HIV;

GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECEPTORS, CXCR4; RECEPTORS, HIV; VIRAL TROPISM;

EID: 84890364111     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt305     Document Type: Article

References (60)

1. Lusso P. HIVand the chemokine system: 10 years later. EMBOJ 2006; 25: 447-56.
2. Berger EA, DomsRW, Fenyö EMet al. Anewclassificationfor HIV-1.Nature 1998; 391: 240.
3. Cornelissen M, Hogervorst E, Zorgdrager F et al. Maintenance of syncytium-inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp120 V2 domain without fixed positions, elongation, or relocated N-linked glycosylation sites. AIDS Res Hum Retroviruses 1995; 11: 1169-75.
4. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J et al. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotypeassociated changes in the V3 loop. J Virol 2002; 76: 3852-64.
5. HuangW, Toma J, Fransen S et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 2008; 82: 5584-93.
6. Dimonte S, Babakir-Mina M, Mercurio Fet al. Selected amino acid changes in HIV-1 subtype C gp41 are associated with specific gp120 (V3) signatures in the regulation of co-receptor usage. Virus Res 2012; 168: 73-83.
7. Sierra S, Kaiser R, Thielen A et al. Genotypic coreceptor analysis. Eur J Med Res 2007; 12: 453-62.
8. Rose JD, Rhea AM, Weber J et al. Current tests to evaluate HIV-1 coreceptor tropism. Curr Opin HIVAIDS 2009; 4: 136-42.
9. Sing T, Low AJ, Beerenwinkel N et al. Predicting HIV coreceptor usage on the basis of geneticandclinicalcovariates. Antivir Ther2007;12:1097-106.
10. McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 2517-25.
11. McGovernRA, ThielenA, Portsmouth S et al. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatmentnaïve patients of the MERIT trial. J Acquir Immune Defic Syndr 2012; 61: 279-86.
12. Vandekerckhove LP, Wensing AM, Kaiser R et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11: 394-407.
13. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011; 13: 77-108.
14. Keele BF, Giorgi EE, Salazar-Gonzalez JF et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105: 7552-7.
15. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat Rev Microbiol 2006; 4: 312-7.
16. Schuitemaker H, van't Wout AB, Lusso P. Clinical significance of HIV-1 coreceptor usage. J Transl Med 2011; 9 Suppl 1: S5.
17. Esbjörnsson J, Månsson F, Martínez-Arias W et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease-indication of an evolving epidemic in West Africa. Retrovirology 2010; 7: 23.
18. Revilla A, Delgado E, Christian EC et al. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. AIDS Res Hum Retroviruses 2011; 27: 889-901.
19. Pé rez-á lvarez L, Delgado E, Villahermosa ML et al. Biological characteristics of newly described HIV-1 BG recombinants in Spanish individuals. AIDS 2002; 16: 669-72.
20. Pé rez-á lvarez L, Muñoz M, Delgado E et al. Isolation and biological characterization of HIV-1 BG intersubtype recombinants and other genetic forms circulating in Galicia, Spain. J Med Virol 2006; 78: 1520-8.
21. Cuevas MT, Fernández-García A, Pinilla M et al. Short communication: Biological and genetic characterization of HIV type 1 subtype B and nonsubtype B transmitted viruses: usefulness for vaccine candidate assessment. AIDS Res Hum Retroviruses 2010; 26: 1019-25.
22. Bártolo I, Abecasis AB, BorregoPet al. Originandepidemiological history of HIV-1 CRF14_BG. PLoS One 2011; 6: e24130.
23. Delgado E, Thomson MM, Villahermosa ML et al. Identification of a newly characterized HIV-1 BG intersubtype circulating recombinant form in Galicia, Spain, which exhibits a pseudotype-like virion structure. J Acquir Immune Defic Syndr 2002; 29: 536-43.
24. Thomson MM, Delgado E, Manjón N et al. HIV-1 genetic diversity in Galicia Spain: BG intersubtype recombinant viruses are circulating among injecting drug users. AIDS 2001; 15: 509-16.
25. Esteves A, Parreira R, Venenno T et al. Molecular epidemiology of HIV type 1 infection in Portugal: high prevalence of non-B subtypes. AIDS Res Hum Retroviruses 2002; 18: 313-25.
26. Palma AC, Araú jo F, Duque V et al. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 2007; 7: 391-8.
27. Secretaría del PlanNacional sobre el SIDA. Vigilancia Epidemiológica del VIH/SIDAenEspaña. Situación a30de Juniode 2012: Ministeriode Sanidad, Servicios Sociales e Igualdad. http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/home.htm (16 June 2013, date last accessed).
28. Katoh K, Toh H. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform 2008; 9: 286-98.
29. Stamatakis A, Hoover P, Rougemont J. A rapid bootstrap algorithm for the RAxML web servers. Syst Biol 2008; 57: 758-71.
30. Lengauer T, Sander O, Sierra S et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25: 1407-10.
31. Fouchier RA, Groenink M, Kootstra NA et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66: 3183-7.
32. Monno L, Scudeller L, LadisaNet al. A greater prevalence of X4 viruses in HIV type 1 intravenous drug users reflects a CD4+ effect. AIDS Res Hum Retroviruses 2011; 27: 1029-31.
33. De Mendoza C, Rodríguez C, GarcíaFet al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007; 59: 698-704.
34. Frange P, Galimand J, Goujard C et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009; 64: 135-41.
35. Raymond S, Delobel P, Mavigner M et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 2010; 24: 2305-12.
36. Huang W, Toma J, Stawiski E et al. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses 2009; 25: 795-802.
37. Raymond S, Saliou A, Nicot F et al. Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing. AIDS 2011; 25: 1668-70.
38. Eshleman SH, Husnik M, Hudelson S et al. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtypeamongmenwhohave sex withmenwith recent HIV-1 infection. AIDS 2007; 21: 1165-74.
39. Brumme ZL, Goodrich J, Mayer HB et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192: 466-74.
40. Simon B, Grabmeier-Pfistershammer K, Rieger A et al. HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS 2010; 24: 2051-8.
41. Frange P, Chaix ML, Raymond S et al. Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol 2010; 48: 3487-91.
42. Cilliers T, Nhlapo J, CoetzerMet al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003; 77: 4449-56.
43. Pollakis G, Abebe A, Kliphuis A et al. Phenotypic and genotypic comparisons of CCR5-and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 2004; 78: 2841-52.
44. Tscherning C, Alaeus A, Fredriksson R et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998; 241: 181-8.
45. Ping LH, Nelson JA, Hoffman IF et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol 1999; 73: 6271-81.
46. Chalmet K, Dauwe K, Foquet L et al. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. J Infect Dis 2012; 205: 174-84.
47. HIV-GRADE. Homepage. http://www.hiv-grade.de/cms/grade/homepage. html (16 June 2013, date last accessed).
48. Obermeier M, SymonsJ, Wensing AM. HIVpopulation genotypic tropism testing and its clinical significance. Curr Opin HIVAIDS 2012; 7: 470-7.
49. Wambui V, Kiptoo MK, Kinyua JG et al. Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype D to be CXCR4 tropic. AIDS Res Ther 2012; 9: 22.
50. Ataher Q, Portsmouth S, Napolitano LA et al. The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. J Int AIDS Soc 2012; 15: 2.
51. Delgado E, Fernández-García A, Vega Y et al. Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes. J Antimicrob Chemother 2012; 67: 25-31.
52. Díez-Fuertes F, Delgado E, Vega Y et al. Improvement of HIV-1 coreceptor tropism prediction employing selected nucleotide positions of the env gene in a Bayesian network classifier. J Antimicrob Chemother 2013; 68: 1471-85.
53. Santoro MM, Armenia D, Fabeni L et al. The lowest X4 Geno2pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. Clin Microbiol Infect 2012; 18: E289-98.
54. Shepherd JC, Jacobson LP, QiaoWet al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 2008; 198: 1104-12.
55. Waters L, Mandalia S, Randell P et al. The impact of HIV tropism on decrease in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46: 1617-23.
56. Goetz MB, Leduc R, Kostman JR et al. Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr 2009; 50: 259-66.
57. Koot M, van Leeuwen R, de Goede RE et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999; 179: 254-8.
58. Peeters M, Vincent R, Perret JL et al. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 115-21.
59. Bártolo I, Camacho R, Barroso H et al. Rapid clinical progression to AIDS and death in a persistently seronegative HIV-1 infected heterosexual young man. AIDS 2009; 23: 2359-62.
60. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.